The lymphocyte proliferative responses to respiratory syncytial virus (RSV) were evaluated for 10 healthy adult donors and compared with proliferative responses to a chimeric glycoprotein (FG glycoprotein) which consists of the extracellular domains of both the F and G proteins of RSV and which is produced from a recombinant baculovirus. The lymphocytes of all 10 donors responded to RSV, and the proliferative responses to the whole virus were highly correlated with the responses to the FG glycoprotein. These data suggested that one or both of these glycoproteins of RSV were major target structures for stimulation of the human lymphocyte proliferative response among virus-specific memory T cells. The lymphocytes of four donors were evaluated further for their proliferative responses to a nested set of overlapping peptides modeled on the extraceliular and cytoplasmic domains of the F protein of RSV. Strikingly, the lymphocytes of all 4 donors responded primarily to a region defined by a single peptide spanning residues 338 to 355, and the lymphocytes of 2 donors responded to an overlapping peptide spanning residues 328 to 342 also, thus defining a region of the Fl subunit within residues 328 to 355 that may circumscribe an immunodominant site for stimulation of human T cells from a variety of individuals. This region of the F protein is highly conserved among A and B subgroup viruses. As revealed by monoclonal antibody blocking studies, the lymphocytes responding to this antigenic site had characteristics consistent with T helper cells. Similar epitope mapping studies were performed with BALB/c mice immunized with the FG protein in which a relatively hydrophobic peptide spanning residues 51 to 65 within the F2 subunit appeared to be the major T cell recognition determinant. The data are discussed with respect to an antigenic map of the F protein and the potential construction of a synthetic vaccine for RSV.
The lymphocyte proliferative responses to respiratory syncytial virus (RSV) were evaluated for 10 healthy adult donors and compared with proliferative responses to a chimeric glycoprotein (FG glycoprotein) which consists of the extracellular domains of both the F and G proteins of RSV and which is produced from a recombinant baculovirus. The lymphocytes of all 10 donors responded to RSV, and the proliferative responses to the whole virus were highly correlated with the responses to the FG glycoprotein. These data suggested that one or both of these glycoproteins of RSV were major target structures for stimulation of the human lymphocyte proliferative response among virus-specific memory T cells. The lymphocytes of four donors were evaluated further for their proliferative responses to a nested set of overlapping peptides modeled on the extraceliular and cytoplasmic domains of the F protein of RSV. Strikingly, the lymphocytes of all 4 donors responded primarily to a region defined by a single peptide spanning residues 338 to 355, and the lymphocytes of 2 donors responded to an overlapping peptide spanning residues 328 to 342 also, thus defining a region of the Fl subunit within residues 328 to 355 that may circumscribe an immunodominant site for stimulation of human T cells from a variety of individuals. This region of the F protein is highly conserved among A and B subgroup viruses. As revealed by monoclonal antibody blocking studies, the lymphocytes responding to this antigenic site had characteristics consistent with T helper cells. Similar epitope mapping studies were performed with BALB/c mice immunized with the FG protein in which a relatively hydrophobic peptide spanning residues 51 to 65 within the F2 subunit appeared to be the major T cell recognition determinant. The data are discussed with respect to an antigenic map of the F protein and the potential construction of a synthetic vaccine for RSV.
Human respiratory syncytial virus (RSV) is a member of the family Paramyxoviridae and has a single-stranded RNA genome which encodes at least 10 unique viral proteins within infected cells (7, 8, 13) . RSV is the leading cause of severe lower respiratory tract infection in infants, and most, if not all, children become infected with RSV during the first few years of life. Intense research efforts have recently focused on characterizing both the virus structural proteins and the host immune responses which may contribute to protection from this important human pathogen. The two major surface glycoproteins of RSV, the G protein and the F protein, function in attachment to and fusion of susceptible host cells, respectively (17, 38) . Polyclonal antibodies or monoclonal antibodies (MAbs) to the G or the F protein neutralize virus infectivity in vitro (2, 25, 37, 38, 40) and provide passive protection in experimental animal models (30, 39) . The important contributions of the G and F glycoproteins in providing protection against RSV infection in experimental animals have been further demonstrated by immunization with recombinant vaccinia viruses expressing the glycoproteins of RSV (9, 15, 20, 22) or by immunization with purified glycoproteins derived either from infected cells (36) or from recombinant baculovirus (6, 41) .
RSV infection in humans and in experimental animals induces a vigorous cell-mediated immune response. The target proteins for RSV-specific cytotoxic T lymphocytes have been identified as the F protein, the nucleocapsid (N) protein, and the 22-kDa membrane-associated protein (4, 19, 23, 26) . Although T-cell proliferative responses have been extensively documented after natural RSV infection or im-* Corresponding author. munization of humans (10, 16, 28, 29) , the viral proteins which elicit this response have not been precisely identified. In this study, we investigated the human lymphocyte proliferative response to whole RSV antigens in comparison to the proliferative response to a chimeric protein containing the extracellular domains of both the F and G glycoproteins as a method to determine the relevance of these two major glycoproteins to this cellular immune response. We then further defined a subset of T-cell-stimulating epitopes within the F protein of RSV by using a nested set of overlapping synthetic peptides. This topological identification of antigenic sites which stimulate human T-cell-mediated immune function may be important for the construction of a safe and effective vaccine against RSV.
MATERIALS AND METHODS
Virus and the FG glycoprotein. Human RSV A2 was propagated in HEp-2 cells and titrated by plaque assay under 0.5% agarose. The cDNA clones containing the complete sequences for the F and G proteins of RSV A2 were received in pBR322 from G. W. Wertz (clones F-A25 and G-16) and manipulated for expression of the chimeric FG protein from the polyhedrin promoter of baculovirus, as previously described in detail (42) . The chimeric FG glycoprotein contained the signal and extracellular regions of the F glycoprotein fused to the extracellular region of the G glycoprotein and contained a termination codon just upstream of the anchor region of the G sequence. The FG glycoprotein was secreted from Sf9 cells infected with the recombinant baculovirus and purified to apparent homogeneity by a combination of cation-exchange and immunoaffinity chromatographies as described previously (6) . were synthesized, purified, and used to restimulate lymphoproliferation in PBMC from four individual donors selected as representative of the panel described above. The PBMC from two donors with moderate responses to RSV and the FG glycoprotein (donors 5 and 10b from Fig. 1 ) and from two donors with vigorous responses to RSV and the FG glycoprotein (donors 12 and 1 from Fig. 1) were cultured in the presence of each individual synthetic peptide, and proliferation was assayed 5 days after restimulation. Figure 2 reveals the lymphoproliferative responses of each of these four donors to the entire panel of overlapping synthetic peptides modeled on the F protein of RSV. As expected, when the panel of the four individual donors was evaluated, several peptides were found to stimulate lymphoproliferation. However, two donors (donors 1 and 12) showed a response, albeit modest, to a peptide spanning residues 131 to 145 or its overlapping peptide spanning residues 141 to 155 (peptides 12 and 13, respectively, in Fig. 2) . Remarkably, all four donors responded predominately to a single synthetic peptide spanning residues 338 to 355 (peptide 33 in Fig. 2) , and two of these four donors also responded to the overlapping peptide spanning residues 328 to 342 (peptide 32 in Fig.  2 ). These data suggested that the region spanning residues 328 to 355 contained an immunodominant epitope for all four of our tested donors.
HLA class II antigen expression in donors responding to the immunodominant peptide epitope (residues 338 to 355) or to whole RSV. The striking result obtained with all four donors (i.e., responding predominantly to a single peptide) prompted us to look at the HLA class II phenotypes of these individuals. Furthermore, it was of interest to compare these phenotypes with the class II phenotype of donor 14, the single donor whose lymphoproliferative response to the FG glycoprotein did not correlate with the response to whole RSV. As shown in Table 1 , none of the four donors (donor 1, 5, 10, or 12) who responded to the immunodominant F peptide (residues 338 to 355) shared a single class II major histocompatibility complex (MHC) allele, suggesting that this peptide could be presented by more than one allele. Donors 1 and 12 shared alleles DR4 and DRw53 (Table 1) , and PBMC from these donors recognized the overlapping F peptide (residues 328 to 342) (Fig. 2) . Furthermore, it appeared that DR1, DR3, DRw52, DQwl, and DQw2 were not important in the proper processing and presentation of the FG glycoprotein since donor 14 expressed each of these alleles (Table 1 ) and responded very poorly to the FG glycoprotein despite a good lymphoproliferative response to whole RSV (Fig. 1) . Only alleles DRw15(2) and DQw6(wl) could be detected for donor 2 (data not shown), the single donor showing a low response to RSV and no response to the FG glycoprotein (Fig. 1) to monomorphic determinants of HLA-DR, MAb to CD4, or MAb to CD1 (a surface determinant expressed only on thymocytes), and the percent inhibition of proliferation by MAbs was determined (Fig. 3) . For donor 12, lymphoproliferation induced by either 50 or 5 ,ug of F peptide (residues 338 to 355) per ml was strongly inhibited by MAb to DR determinants or by MAb to CD4, while inhibition by the control MAb to CD1 was negligible (Fig. 3, left) . For donor 10b, proliferation induced by 50 ,ug of peptide per ml was specifically inhibited by MAb to DR determinants and proliferation induced by 5 ,ug of peptide per ml was specifically inhibited by MAb to either DR or CD4 determinants (Fig. 3 , right panel). These data suggested that presentation of the F peptide (residues 338 to 355) was class II MHC restricted and that the responding lymphocytes were of the CD4+, T helper cell phenotype. Lymphoproliferative responses to overlapping peptides of the F protein in mice primed to the FG glycoprotein. Since mice of the H-2d haplotype have proven to be a valuable model for the study of human RSV pathogenesis (12, 31) , it was of interest to immunize BALB/c mice with the FG glycoprotein and to determine the recognition of the F protein moiety by using our panel of overlapping synthetic peptides. The results of a representative experiment are shown in Fig. 4 . The lymphocytes from FG-primed BALB/c mice responded to restimulation with either RSV or FG and responded significantly to a single synthetic peptide spanning residues 51 to 65 within the F2 subunit of the F protein (peptide 4 in Fig. 4) . The proliferative response to this peptide was highly reproducible among several experiments with BALB/c mice (data not shown), and this response could be abrogated by MAb to CD4 determinants (L3T4) and significantly reduced by MAb to IE determinants but not by MAb to IA determinants (Fig. 5) .
DISCUSSION
These studies verified a role for the major glycoproteins of RSV in stimulation of the T lymphocyte proliferative response following natural infection of the human host. The high degree of correlation between the lymphoproliferative response to whole virus and the response to the chimeric FG glycoprotein further suggested that one or both of these glycoproteins were dominant target structures for human T-cell recognition, at least within the adult population, in which repeated exposure to or infection with RSV was likely to have occurred. Although these are the first studies to investigate the RSV protein specificity of the lymphoproliferative response in humans, our study design could not distinguish the contribution of each individual glycoprotein to this response. However, studies of mice (24) have previously identified a dominant role for the F glycoprotein versus that of the G glycoprotein in stimulation of the RSV-specific murine T helper cell response following immunization with recombinant vaccinia virus vectors, thus supporting the notion that the human response we observed in our studies may have been similarly dominated by recognition of the F moiety of the FG glycoprotein. Since the lymphoproliferative response to RSV has been reported to gradually rise during the 3 years following primary infection (10), it will be important to determine whether there is a corresponding correlation between the lymphoproliferative responses to whole virus and to the FG glycoprotein following primary   FIG. 2 . Human lymphoproliferative response to synthetic peptides modeled on the F protein of RSV. PBMC from four healthy adult donors selected from the group described in the legend to Fig. 1 (5, 11, 18) , Western immunoblotting (33, 34) , and analysis of the binding of MAbs or polyclonal antibodies to proteolytic digestion fragments or synthetic peptides (1, 18, 21, 27, 32) have defined four to five antigenic sites on the F glycoprotein and two to three antigenic sites on the G glycoprotein. At least one immunodominant site for binding of human postinfection serum with high neutralization titer has been localized to a disulfidebonded loop of the G protein which has been identified for both the A and B subgroups of RSV (1, 21) . At least one neutralization determinant maps to the Fl subunit of the fusion protein (5, 18, (32) (33) (34) (35) , and a site for binding of fusion-inhibiting MAb maps proximal to a neutralization determinant on the Fl subunit (35) . At least some of these fusion-inhibiting and neutralizing antibody-binding sites appear to be continuous, linear determinants (18, 27, 32, 34, 35) which are highly conserved among group A and B isolates of RSV (2, 3, 18, 32) . The highly conserved nature of neutralization determinants on the F protein of RSV coupled with the purported linear, sequential nature of these sites and of the highly antigenic loop site on the G protein (1, 21) suggests that incorporation of these sites into synthetic vaccines or their expression from prokaryotic vectors might require minimal protein refolding and reconfiguration. Thus, the identification of an immunodominant human T-cellstimulating site on the F glycoprotein, as reported herein, would be an important, additional component for such a proposed synthetic or subunit vaccine for RSV.
